Keyphrases
Transgender
100%
Body Composition
86%
Gonadotropin-releasing Hormone
70%
Gender Diverse Youth
69%
Transgender Females
66%
Gender Diverse
63%
Pubertal Suppression
50%
Transgender Male
50%
Israel
49%
Blood Pressure
49%
Pressure Dynamics
47%
Post-streptococcal Reactive Arthritis
47%
Metabolic Syndrome Components
47%
Fertility Preservation
37%
Gender-affirming Hormone Therapy
30%
Adolescent Males
29%
Mental Health
29%
Prepubertal children
26%
Adverse Effects
26%
Testosterone
26%
Rheumatic Fever
26%
Gender Dysphoria
26%
Older Adults
23%
Testosterone Replacement Therapy
23%
Hypothyroidism
23%
Parathyroid Adenoma
23%
Preservation Rate
23%
Percutaneous Coronary Intervention
23%
Female Adolescents
23%
Primary Hyperparathyroidism (pHPT)
23%
Estradiol Treatment
23%
Cardiac Evaluation
23%
Familial Dysautonomia
23%
Distinct Entity
23%
Adolescent Mental Health
23%
Semen Quality
23%
Sectional Analysis
23%
COVID-19
23%
Gender Nonconforming
23%
Intracytoplasmic Sperm Injection
23%
Final Height
23%
Childhood-onset Systemic Lupus Erythematosus
23%
Final Adult Height
23%
Body Composition Assessment
23%
Gender-affirming Treatment
23%
Nave
23%
Metabolic Syndrome
23%
Cardiometabolic Health
23%
Premature Adrenarche
23%
Gender-related
23%
Medicine and Dentistry
Transgender
87%
Metabolic Syndrome
47%
Fertility Preservation
37%
Hormone Therapy
33%
Cross Sectional Study
29%
Side Effect
26%
Systemic Lupus Erythematosus
23%
Hypothyroidism
23%
Parathyroid Adenoma
23%
Gonadorelin Agonist
23%
Reactive Arthritis
23%
Primary Hyperparathyroidism
23%
Percutaneous Coronary Intervention
23%
Intracytoplasmic Sperm Injection
23%
Adrenarche
23%
Prematurity
23%
Gender Identity Disorder
23%
Patient Referral
23%
Echocardiography
15%
Major Adverse Cardiac Event
13%
Body Mass Index
13%
Dyslipidemia
11%
Oligospermia
9%
Triacylglycerol
9%
Postoperative Complication
9%
Pediatrics
8%
High Density Lipoprotein Cholesterol
7%
Bioelectrical Impedance Analysis
6%
Sex Hormone
6%
Brain Development
6%
Adverse Effect
6%
Elevated Blood Pressure
6%
Mitral Insufficiency
5%
